Galderma has provided a progress update on its Biologics License Application (BLA) for RelabotulinumtoxinA, a botulinum toxin candidate under FDA review. The update confirms ongoing regulatory engagement but does not disclose an expected decision date.
Regulatory
Galderma Provides Update on RelabotulinumtoxinA BLA Review — Third Botulinum Toxin Competitor Advances
Galderma's neuromodulator candidate moves through FDA Biologics License Application review.
A third botulinum toxin competitor advances through FDA review, fragmenting the market and pressuring toxin rebate structures.
RelabotulinumtoxinA would join Revance's DaxibotulinumtoxinA (Daxxify) as the second non-AbbVie neuromodulator approved in the U.S., fragmenting the botulinum toxin market beyond Botox and Jeuveau. For practices, a third entrant reshapes toxin economics: it pressures rebate structures across Allergan Aesthetics' Allē loyalty program and Evolus's Evolus Rewards, potentially widening access to alternative toxins and forcing manufacturers to compete on per-unit pricing and loyalty terms. Galderma's existing dermatology footprint (Restylane, Sculptra) positions it to bundle RelabotulinumtoxinA into practice agreements.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.